Similar articles for PMID: 23256518

Year	Number of Results
1994	3
1995	1
1996	2
1997	2
1998	2
2000	5
2001	2
2003	1
2004	3
2005	3
2006	2
2007	5
2008	3
2009	6
2010	20
2011	18
2012	10
2013	8
2014	5
2015	9
2016	1
2017	12
2018	25
2019	26
2020	32
2021	35
2022	38
2023	8
2024	1

1

Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.

Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M. Comi G, et al. Expert Opin Pharmacother. 2013 Jan;14(1):123-36. doi: 10.1517/14656566.2013.754012. Epub 2012 Dec 21. Expert Opin Pharmacother. 2013. PMID: 23256518 Review.

2

Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.

Sipe JC. Sipe JC. Expert Rev Neurother. 2010 Mar;10(3):365-75. doi: 10.1586/ern.10.12. Expert Rev Neurother. 2010. PMID: 20187859 Review.

3

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.

Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP. Rammohan K, et al. Drugs. 2020 Dec;80(18):1901-1928. doi: 10.1007/s40265-020-01422-9. Drugs. 2020. PMID: 33247831 Free PMC article. Review.

4

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S; CLARITY study group. Giovannoni G, et al. Lancet Neurol. 2011 Apr;10(4):329-37. doi: 10.1016/S1474-4422(11)70023-0. Lancet Neurol. 2011. PMID: 21397565

5

Cladribine: mode of action and implications for treatment of multiple sclerosis.

Leist TP, Weissert R. Leist TP, et al. Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35. doi: 10.1097/WNF.0b013e318204cd90. Clin Neuropharmacol. 2011. PMID: 21242742 Review.

6

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.

Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group. Cook S, et al. Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228029 Clinical Trial.

7

CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.

Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ. Miravalle AA, et al. Neurodegener Dis Manag. 2021 Apr;11(2):99-111. doi: 10.2217/nmt-2020-0059. Epub 2021 Feb 1. Neurodegener Dis Manag. 2021. PMID: 33517769 Free article.

8

Cladribine tablets' potential in multiple: sclerosis treatment.

Costello K, Sipe JC. Costello K, et al. J Neurosci Nurs. 2008 Oct;40(5):275-80. doi: 10.1097/01376517-200810000-00005. J Neurosci Nurs. 2008. PMID: 18856248 Review.

9

Emerging oral drugs for relapsing-remitting multiple sclerosis.

Gasperini C, Ruggieri S. Gasperini C, et al. Expert Opin Emerg Drugs. 2011 Dec;16(4):697-712. doi: 10.1517/14728214.2011.642861. Epub 2011 Dec 7. Expert Opin Emerg Drugs. 2011. PMID: 22148963 Review.

10

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM. Holmøy T, et al. Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Expert Opin Pharmacother. 2017. PMID: 28858531 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

248 results

Results by year